Health outcomes among patients receiving oseltamivir

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 4, 2004, Pages 227-237

  Enger, Cheryl ^a   Nordstrom, Beth L ^a   Thakrar, Bharat ^b   Sacks, Susan ^b   Rothman, Kenneth J ^a  

^a Ingenix Inc   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Adverse events; Incidence rate ratios; Influenza; Oseltamivir

Indexed keywords

AMANTADINE; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTITUSSIVE AGENT; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHMA; BRONCHITIS; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG APPROVAL; DRUG FATALITY; DRUG USE; ENDOCARDITIS; EPILEPSY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MENTAL DISEASE; MIGRAINE; MYOCARDITIS; NEUROLOGIC DISEASE; NEUROSIS; OTITIS MEDIA; OUTCOMES RESEARCH; PATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SINUSITIS; STRABISMUS; STROKE; SYNCOPE; TREATMENT OUTCOME; VIRUS ENCEPHALITIS; VIRUS MENINGITIS;

ACETAMIDES; ADULT; AGED; ANTIVIRAL AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MENTAL DISORDERS; MIDDLE AGED; OSELTAMIVIR; RESPIRATORY TRACT DISEASES;

EID: 1942520311     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.845     Document Type: Article

References (12)

1. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998; 42: 640-646.
2. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845-1850.
3. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016-1024.
4. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240-1246.
5. Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000; 5: 205-213.
6. Roche Laboratories, Inc. Tamiflu™ (oseltamivir phosphate) capsules [Package insert]. Roche Laboratories, Inc.: Nutley, NJ, 2000.
7. Centers for Disease Control and Prevention: prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2001; 50(RR04): 1-46.
8. Centers for Disease Control and Prevention: neuraminidase inhibitors for treatment of influenza A and B infections: recommendations of the Advisory Committee in Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999; 48(RR-14): 1-9.
9. Management of Influenza in the Southern Hemisphere Trialists (MIST) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-1881.
10. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-261.
11. Lanza LL, Dreyer NA, Schultz N, Walker AM. Use of insurance claims in epidemiologic research: identification of peptic ulcers, GI bleeding, pancreatitis, hepatitis, and renal disease. Pharmacoepidemiol Drug Safe 1995; 4: 239-248.
12. Quam I, Ellis LB, Venus P, Clouse J, Taylor CG, Leatherman S. Using claims data for epidemiologic research: the concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993; 31: 498-507.